Tumor necrosis factor

• Tumor necrosis factor α, and agonist and antagonists of cannabinoid receptor type 1 and type 2 alter the immunophenotype of stem cells from human exfoliated deciduous teeth (02 Sep 2024)
  
• The Interplay between Cannabinoid Receptors and Microglia in the Pathophysiology of Alzheimer’s Disease (02 Sep 2024)
  
• The Impact of the CB2 Cannabinoid Receptor in Inflammatory Diseases: An Update (02 Sep 2024)
  
• Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity (02 Sep 2024)
  
• CB2 Cannabinoid Receptor as a Potential Target in Myocardial Infarction: Exploration of Molecular Pathogenesis and Therapeutic Strategies (02 Sep 2024)
  
• Expression of cannabinoid (CB1 and CB2) and cannabinoid-related receptors (TRPV1, GPR55, and PPARα) in the synovial membrane of the horse metacarpophalangeal joint (29 Aug 2024)
  
• Cannabinoid WIN55,212-2 reprograms monocytes and macrophages to inhibit LPS-induced inflammation (29 Aug 2024)
  
• Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases (28 Aug 2024)
  
• Anti-Inflammatory and Pro-Autophagy Effects of the Cannabinoid Receptor CB2R: Possibility of Modulation in Type 1 Diabetes (21 Aug 2024)
  
• Epigenetic Regulation of Cannabinoid-Mediated Attenuation of Inflammation and Its Impact on the Use of Cannabinoids to Treat Autoimmune Diseases (20 Aug 2024)
  
• Antidepressant-Like Effect of Terpineol in an Inflammatory Model of Depression: Involvement of the Cannabinoid System and D2 Dopamine Receptor (20 Aug 2024)
  
• Structure–Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives (19 Aug 2024)
  
• MicroRNA-29a Attenuates Diabetic Glomerular Injury through Modulating Cannabinoid Receptor 1 Signaling (19 Aug 2024)
  
• Monoacylglycerol lipase regulates cannabinoid receptor 2-dependent macrophage activation and cancer progression (18 Aug 2024)
  
• In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid (18 Aug 2024)
  
• Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease (18 Aug 2024)
  
• Inflammation and cancer: friend or foe? (24 May 2024)
  
• Effect of the Cannabinoid Receptor-1 antagonist SR141716A on human adipocyte inflammatory profile and differentiation (13 May 2024)
  
• Cannabinoid Receptor 1 Blockade Attenuates Obesity and Adipose Tissue Type 1 Inflammation Through miR-30e-5p Regulation of Delta-Like-4 in Macrophages and Consequently Downregulation of Th1 Cells (13 May 2024)
  
• Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance (27 Feb 2023)
  
• Components of the Endocannabinoid System and Effects of Cannabinoids Against Bone Diseases: A Mini-Review (13 Aug 2022)
  
• The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation (05 Aug 2022)
  
• Botanically-Derived Δ9-Tetrahydrocannabinol and Cannabidiol, and Their 1:1 Combination, Modulate Toll-like Receptor 3 and 4 Signalling in Immune Cells from People with Multiple Sclerosis (05 Aug 2022)
  
• Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action (31 Jul 2022)
  
• Endothelial dysfunction and angiogenesis: what is missing from COVID-19 and cannabidiol story? - Journal of Cannabis Research (26 Jul 2022)
  
• Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review (21 Jul 2022)
  
• Single Compound vs. Whole Plant CBD (20 Jul 2022)